LFMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LifeMD Inc (LFMD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential upside based on analyst upgrades and price targets, the lack of significant positive trading signals, weak financial performance in the latest quarter, and neutral technical indicators suggest waiting for a clearer entry point.
The MACD is slightly positive at 0.00232, but contracting, indicating limited momentum. RSI is neutral at 53.511, showing no overbought or oversold conditions. Moving averages are converging, and the stock is trading near its support level of 3.813, with resistance at 4.561. Overall, the technical indicators do not suggest a strong trend in either direction.
Analysts have upgraded the stock with price targets ranging from $8 to $10, citing growth in virtual care and weight loss management programs. The company's focus on GLP-1 drugs aligns with broader market trends, and gross margin improved YoY.
The company's Q4 financials show a significant drop in net income (-435.72% YoY) and EPS (-392.86% YoY), which raises concerns about profitability. There are no recent news or significant insider/hedge fund trading trends to support a bullish case.
In Q4 2025, revenue grew by 3.84% YoY, but net income and EPS dropped significantly, reflecting poor profitability. Gross margin improved to 87.14%, up 7.04% YoY, but this is overshadowed by the steep decline in net income and EPS.
Analysts are bullish, with upgrades from Mizuho, Freedom Capital, and H.C. Wainwright. Price targets range from $8 to $10, suggesting significant upside from the current price of $3.91. Analysts highlight the company's growth potential in virtual care and weight loss management.
